Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 2/29/2024 | 8/31/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 30.9% | 4,135.7% | -97.5% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 49.9% | 38.4% | 100% | 30.6% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -158.9% | -63.9% | -3,635.7% | -312.2% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | -£0 | £0 | £0 |
| Net Income | -£0 | -£0 | £0 | -£0 |
| % Margin | -162.8% | -92.7% | 29,142.9% | -360.9% |
| EPS | -0.034 | -0.015 | 0.11 | -0.058 |
| % Growth | -130.4% | -113.5% | 289.7% | – |
| EPS Diluted | -0.034 | -0.015 | 0.11 | -0.058 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -150.8% | -50.9% | -2,628.6% | -239.6% |